The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) and rare paediatric disease designation ...

Arbor Biotechnologies Inc.’s ABO-101 has been awarded orphan drug and rare pediatric disease designations by the FDA for the treatment of primary hyperoxaluria type 1 (PH1).

TORONTO – The Ontario government is connecting more people to the care they need by ensuring Ontarians, of all ages, living with rare diseases have faster and easier access to new and emerging ...